Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility

Breast Cancer Research

Volumn 12, Issue 5, 2010, Pages

  Leong, David T ^a,b   Lim, Joleen ^a   Goh, Xuewei ^a   Pratap, Jitesh ^c,d   Pereira, Barry P ^b   Kwok, Hui Si ^a   Nathan, Saminathan Suresh ^e   Dobson, Jason R ^c   Lian, Jane B ^c   Ito, Yoshiaki ^a   Voorhoeve, P Mathijs ^e,f   Stein, Gary S ^c   Salto Tellez, Manuel ^a,g   Cool, Simon M ^e,h   van Wijnen, Andre J ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

^g NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^h INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; COMPLEMENTARY DNA; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; FLAVONOID; RUNX2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; OSTEOBLAST; POLYACRYLAMIDE GEL ELECTROPHORESIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL; WESTERN BLOTTING; ADENOCARCINOMA; BIOSYNTHESIS; BREAST TUMOR; CELL MOTION; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

ADENOCARCINOMA; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; NEOPLASM METASTASIS; OSTEOBLASTS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 77958522312     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2762     Document Type: Article

References (69)

1. van Wijnen AJ, Stein GS, Gergen JP, Groner Y, Hiebert SW, Ito Y, Liu P, Neil JC, Ohki M, Speck N. Nomenclature for Runt-related (RUNX) proteins. Oncogene 2004, 23:4209-4210. 10.1038/sj.onc.1207758, 15156174.
2. Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res 2008, 99:33-76. full_text, 18037406.
3. Friedman AD. Cell cycle and developmental control of hematopoiesis by Runx1. J Cell Physiol 2009, 219:520-524. 10.1002/jcp.21738, 19235904.
4. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, Salto-Tellez M. Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 2009, 1796:315-331.
5. Kilbey A, Terry A, Cameron ER, Neil JC. Oncogene-induced senescence: an essential role for Runx. Cell Cycle 2008, 7:2333-2340. 2562501, 18677118.
6. Blyth K, Cameron ER, Neil JC. The runx genes: gain or loss of function in cancer. Nat Rev Cancer 2005, 5:376-387. 10.1038/nrc1607, 15864279.
7. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006, 25:589-600. 10.1007/s10555-006-9032-0, 17165130.
8. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 2005, 102:1454-1459. 10.1073/pnas.0409121102, 547873, 15665096.
9. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, Stein GS, Gerstenfeld LC. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases associated osteolytic disease. Cancer Res 2004, 64:4506-4513. 10.1158/0008-5472.CAN-03-3851, 15231660.
10. Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ, Bellahcene A, van Wijnen AJ, Young MF, Lian JB, Stein GS, Gerstenfeld LC. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003, 63:2631-2637.
11. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005, 25:8581-8591. 10.1128/MCB.25.19.8581-8591.2005, 1265732, 16166639.
12. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Runx2 transcriptional activation of Indian hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 2008, 68:7795-7802. 10.1158/0008-5472.CAN-08-1078, 2596479, 18829534.
13. Pratap J, Imbalzano K, Underwood J, Cohet N, Gokul KD, Akech J, van Wijnen AJ, Stein JL, Imbalzano AN, Nickerson JA, Lian JB, Stein GS. Ectopic Runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: Implications for breast cancer progression. Cancer Res 2009, 69:6807-6814. 10.1158/0008-5472.CAN-09-1471, 2742766, 19690135.
14. Shore P. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J Cell Biochem 2005, 96:484-489. 10.1002/jcb.20557, 16052475.
15. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s-6216s. 10.1158/1078-0432.CCR-06-1007, 17062703.
16. Guise TA. Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev 2009, 23:2117-2123. 10.1101/gad.1854909, 2751987, 19759260.
17. Das K, Leong DT, Gupta A, Shen L, Putti T, Stein GS, van Wijnen AJ, Salto-Tellez M. Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur J Cancer 2009, 45:2239-2248. 10.1016/j.ejca.2009.06.021, 2733789, 19632824.
18. Yeung F, Law WK, Yeh CH, Westendorf JJ, Zhang Y, Wang R, Kao C, Chung LW. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem 2002, 277:2468-2476. 10.1074/jbc.M105947200, 11684680.
19. Fowler M, Borazanci E, McGhee L, Pylant SW, Williams BJ, Glass J, Davis JN, Meyers S. RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem 2006, 97:1-17. 10.1002/jcb.20664, 16237704.
20. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003, 56:13-22. 10.1002/pros.10233, 12746842.
21. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen A, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010, 29:811-821. 10.1038/onc.2009.389, 2820596, 19915614.
22. van der Deen M, Akech J, Wang T, FitzGerald TJ, Altieri DC, Languino LR, Lian JB, van Wijnen AJ, Stein JL, Stein GS. The cancer-related Runx2 protein enhances cell growth and responses to andogen and TGFb in prostate cancer cells. J Cell Biochem 2010, 109:828-837.
23. Galindo M, Pratap J, Young DW, Hovhannisyan H, Im HJ, Choi JY, Lian JB, Stein JL, Stein GS, van Wijnen AJ. The bone-specific expression of RUNX2 oscillates during the cell cycle to support a G1 related anti-proliferative function in osteoblasts. J Biol Chem 2005, 280:20274-20285. 10.1074/jbc.M413665200, 2895256, 15781466.
24. Nathan SS, Pereira BP, Zhou YF, Gupta A, Dombrowski C, Soong R, Pho RW, Stein GS, Salto-Tellez M, Cool SM, van Wijnen AJ. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep 2009, 36:153-158. 10.1007/s11033-008-9378-1, 2981062, 18931939.
25. Pereira BP, Zhou Y, Gupta A, Leong DT, Aung KZ, Ling L, Pho RW, Galindo M, Salto-Tellez M, Stein GS, Cool SM, van Wijnen AJ, Nathan SS. Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1). J Cell Physiol 2009, 221:778-788. 10.1002/jcp.21921, 19746444.
26. San Martin IA, Varela N, Gaete M, Villegas K, Osorio M, Tapia JC, Antonelli J, Mancilla E, Pereira BP, Nathan SS, Lian JB, Stein JL, Stein GS, van Wijnen AJ, Galindo M. Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfb in osteosarcoma cells. J Cell Physiol 2009, 221:560-571. 10.1002/jcp.21894, 19739101.
27. Sadikovic B, Yoshimoto M, Chilton-MacNeill S, Thorner P, Squire JA, Zielenska M. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet 2009, 18:1962-1975. 10.1093/hmg/ddp117, 19286668.
28. Bakhshi S, Gupta A, Sharma MC, Khan SA, Rastogi S. Her-2/neu, p-53, and their coexpression in osteosarcoma. J Pediatr Hematol Oncol 2009, 31:245-251. 10.1097/MPH.0b013e318197947e, 19346874.
29. Won KY, Park HR, Park YK. Prognostic implication of immunohistochemical Runx2 expression in osteosarcoma. Tumori 2009, 95:311-316.
30. Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP, Waring P, McArthur GA, Walkley CR, Holloway AJ, Diyagama D, Grim JE, Clurman BE, Bowtell DD, Lee JS, Gutierrez GM, Piscopo DM, Carty SA, Hinds PW. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 2004, 167:925-934. 10.1083/jcb.200409187, 2172443, 15583032.
31. Thomas D, Kansara M. Epigenetic modifications in osteogenic differentiation and transformation. J Cell Biochem 2006, 98:757-769. 10.1002/jcb.20850, 16598744.
32. Stewart M, Terry A, Hu M, O'Hara M, Blyth K, Baxter E, Cameron E, Onions DE, Neil JC. Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene. Proc Natl Acad Sci USA 1997, 94:8646-8651. 10.1073/pnas.94.16.8646, 23059, 9238031.
33. Stewart M, Terry A, O'Hara M, Cameron E, Onions D, Neil JC. til-1: a novel proviral insertion locus for Moloney murine leukaemia virus in lymphomas of CD2-myc transgenic mice. J Gen Virol 1996, 77:443-446. 10.1099/0022-1317-77-3-443, 8601779.
34. Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, Neil JC, Cameron ER. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res 2006, 66:2195-2201. 10.1158/0008-5472.CAN-05-3558, 16489021.
35. Stewart M, Mackay N, Hanlon L, Blyth K, Scobie L, Cameron E, Neil JC. Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas. Cancer Res 2007, 67:5126-5133. 10.1158/0008-5472.CAN-07-0433, 2562448, 17545590.
36. Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, Stein JL, Stein GS. Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 2004, 14:1-41. 10.1615/CritRevEukaryotGeneExpr.v14.i12.10, 15104525.
37. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao Y-H, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997, 89:755-764. 10.1016/S0092-8674(00)80258-5, 9182763.
38. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GWH, Beddington RSP, Mundlos S, Olsen BR, Selby PB, Owen MJ. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997, 89:765-771. 10.1016/S0092-8674(00)80259-7, 9182764.
39. Choi J-Y, Pratap J, Javed A, Zaidi SK, Xing L, Balint E, Dalamangas S, Boyce B, van Wijnen AJ, Lian JB, Stein JL, Jones SN, Stein GS. Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development. Proc Natl Acad Sci USA 2001, 98:8650-8655. 10.1073/pnas.151236498, 37490, 11438701.
40. Lou Y, Javed A, Hussain S, Colby J, Frederick D, Pratap J, Xie R, Gaur T, van Wijnen AJ, Jones SN, Stein GS, Lian JB, Stein JL. A Runx2 threshold for the cleidocranial dysplasia phenotype. Hum Mol Genet 2009, 18:556-568. 10.1093/hmg/ddn383, 2638795, 19028669.
41. Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, Choi J-Y, Komori T, Stein JL, Lian JB, Stein GS, van Wijnen AJ. Cell growth regulatory role of Runx2 during proliferative expansion of pre-osteoblasts. Cancer Res 2003, 63:5357-5362.
42. Kilbey A, Blyth K, Wotton S, Terry A, Jenkins A, Bell M, Hanlon L, Cameron ER, Neil JC. Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res 2007, 67:11263-11271. 10.1158/0008-5472.CAN-07-3016, 2562449, 18056452.
43. Zaidi SK, Pande S, Pratap J, Gaur T, Grigoriu S, Ali SA, Stein JL, Lian JB, van Wijnen AJ, Stein GS. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci USA 2007, 104:19861-19866. 10.1073/pnas.0709650104, 2148388, 18077419.
44. Teplyuk NM, Galindo M, Teplyuk VI, Pratap J, Young DW, Lapointe D, Javed A, Stein JL, Lian JB, Stein GS, van Wijnen AJ. Runx2 regulates G-protein coupled signaling pathways to control growth of osteoblast progenitors. J Biol Chem 2008, 283:27585-27597. 10.1074/jbc.M802453200, 2562077, 18625716.
45. Galindo M, Kahler RA, Teplyuk NM, Stein JL, Lian JB, Stein GS, Westendorf JJ, van Wijnen AJ. Cell cycle related modulations in Runx2 protein levels are independent of lymphocyte enhancer-binding factor 1 (Lef1) in proliferating osteoblasts. J Mol Histol 2007, 38:501-506. 10.1007/s10735-007-9143-0, 17885813.
46. Galindo M, Teplyuk N, Yang X, Young DW, Javed A, Lian JB, Stein JL, Stein GS, van Wijnen AJ. Post-mitotic expression of transcription factor RUNX2 defines a novel regulatory transition during the G1 phase of proliferating pre-osteoblasts [abstract]. J Bone Miner Res 2006, 21:S384.
47. Shen R, Wang X, Drissi H, Liu F, O'Keefe RJ, Chen D. Cyclin d1-Cdk4 induce Runx2 ubiquitination and degradation. J Biol Chem 2006, 281:16347-16353. 10.1074/jbc.M603439200, 2649830, 16613857.
48. Young DW, Hassan MQ, Pratap J, Galindo M, Zaidi SK, Lee SH, Yang X, Xie R, Javed A, Underwood JM, Furcinitti P, Imbalzano AN, Penman S, Nickerson JA, Montecino MA, Lian JB, Stein JL, van Wijnen AJ, Stein GS. Mitotic occupancy and lineage-specific transcriptional control of rRNA genes by Runx2. Nature 2007, 445:442-446. 10.1038/nature05473, 17251981.
49. Young DW, Hassan MQ, Yang X-Q, Galindo M, Javed A, Zaidi SK, Furcinitti P, Lapointe D, Montecino M, Lian JB, Stein JL, van Wijnen AJ, Stein GS. Mitotic retention of gene expression patterns by the cell fate determining transcription factor Runx2. Proc Natl Acad Sci USA 2007, 104:3189-3194. 10.1073/pnas.0611419104, 1805558, 17360627.
50. Teplyuk NM, Zhang Y, Lou Y, Hawse JR, Hassan MQ, Teplyuk VI, Pratap J, Galindo M, Stein JL, Stein GS, Lian JB, van Wijnen AJ. The osteogenic transcription factor Runx2 controls genes involved in sterol/steroid metabolism, including CYP11A1 in osteoblasts. Mol Endocrinol 2009, 23:849-861. 10.1210/me.2008-0270, 2691677, 19342447.
51. Jensen ED, Niu L, Caretti G, Nicol SM, Teplyuk N, Stein GS, Sartorelli V, van Wijnen AJ, Fuller-Pace FV, Westendorf JJ. p68 (Ddx5) interacts with Runx2 and regulates osteoblast differentiation. J Cell Biochem 2008, 103:1438-1451. 10.1002/jcb.21526, 17960593.
52. Teplyuk NM, Haupt LM, Ling L, Dombrowski C, Mun FK, Nathan SS, Lian JB, Stein JL, Stein GS, Cool SM, van Wijnen AJ. The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor/proteoglycan signaling axis in osteoblasts. J Cell Biochem 2009, 107:144-154. 10.1002/jcb.22108, 2918404, 19259985.
53. Franceschi RT, Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: Responsiveness to multiple signal transduction pathways. J Cell Biochem 2003, 88:446-454. 10.1002/jcb.10369, 12532321.
54. Qiao M, Shapiro P, Kumar R, Passaniti A. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway. J Biol Chem 2004, 279:42709-42718. 10.1074/jbc.M404480200, 15304489.
55. Hirsch DS, Shen Y, Wu WJ. Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42. Cancer Res 2006, 66:3523-3530. 10.1158/0008-5472.CAN-05-1547, 16585176.
56. Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism. Cancer Res 1999, 59:5475-5478.
57. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366:2-16. 10.1016/j.gene.2005.10.018, 16377102.
58. Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, Ogita K, Komori T. Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 2004, 166:85-95. 10.1083/jcb.200401138, 2172136, 15226309.
59. Inman CK, Li N, Shore P. Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein. Mol Cell Biol 2005, 25:3182-3193. 10.1128/MCB.25.8.3182-3193.2005, 1069618, 15798204.
60. Inman CK, Shore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 2003, 278:48684-48689. 10.1074/jbc.M308001200, 14506237.
61. Sun L, Vitolo M, Passaniti A. Runt-related gene 2 in endothelial cells: inducible expression and specific regulation of cell migration and invasion. Cancer Res 2001, 61:4994-5001.
62. D'Souza DR, Salib MM, Bennett J, Mochin-Peters M, Asrani K, Goldblum SE, Renoud KJ, Shapiro P, Passaniti A. Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway. J Biol Chem 2009, 284:17947-17955. 10.1074/jbc.M109.002378, 2709386, 19383984.
63. Vitolo MI, Anglin IE, Mahoney WM, Renoud KJ, Gartenhaus RB, Bachman KE, Passaniti A. The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation. Cancer Biol Ther 2007, 6:856-863.
64. Qiao M, Shapiro P, Fosbrink M, Rus H, Kumar R, Passaniti A. Cell cycle-dependent phosphorylation of the RUNX2 transcription factor by cdc2 regulates endothelial cell proliferation. J Biol Chem 2006, 281:7118-7128. 10.1074/jbc.M508162200, 16407259.
65. Sun L, Vitolo MI, Qiao M, Anglin IE, Passaniti A. Regulation of TGFbeta1-mediated growth inhibition and apoptosis by RUNX2 isoforms in endothelial cells. Oncogene 2004, 23:4722-4734. 10.1038/sj.onc.1207589, 15107836.
66. Sun X, Wei L, Chen Q, Terek RM. HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity. J Biol Chem 2009, 284:21881-21890. 10.1074/jbc.M109.019091, 2755912, 19509297.
67. Park HR, Park YK. Differential expression of runx2 and Indian hedgehog in cartilaginous tumors. Pathol Oncol Res 2007, 13:32-37. 10.1007/BF02893438, 17387386.
68. Pei Y, Harvey A, Yu XP, Chandrasekhar S, Thirunavukkarasu K. Differential regulation of cytokine-induced MMP-1 and MMP-13 expression by p38 kinase inhibitors in human chondrosarcoma cells: potential role of Runx2 in mediating p38 effects. Osteoarthritis Cartilage 2006, 14:749-758. 10.1016/j.joca.2006.01.017, 16549373.
69. Papachristou DJ, Papachristou GI, Papaefthimiou OA, Agnantis NJ, Basdra EK, Papavassiliou AG. The MAPK-AP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF. Histopathology 2005, 47:565-574.